BB Biotech AG
ISIN-No.: CH0038389992
YTD: -11.09%
Active share: 83.73
Anzahl Positionen: 31
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Indexed performance (as at: 28.10.2024)
Share price: CHF 36.40 (28.10.2024)
NAV: CHF 43.40 (28.10.2024)
Rolling performance (28.10.2024)
Share Price | NAV | Benchmark | |
28.10.2023 - 28.10.2024 | 5.15% | 28.60% | 25.12% |
28.10.2022 - 28.10.2023 | -31.90% | -31.39% | -15.92% |
28.10.2021 - 28.10.2022 | -26.62% | -9.87% | -8.89% |
28.10.2020 - 28.10.2021 | 44.86% | 19.07% | 21.38% |
Annualized performance (28.10.2024)
Share Price | NAV | Benchmark | |
1 year | 5.15% | 28.60% | 25.12% |
3 years | -19.30% | -7.35% | -2.49% |
5 years | -5.52% | 1.94% | 5.10% |
10 years | 4.16% | 3.35% | 4.15% |
Since Inception p.a. | 9.70% | 10.33% | 9.05% |
Cumulative performance (28.10.2024)
Share Price | NAV | Benchmark | |
1M | -1.22% | 7.29% | 2.02% |
YTD | -11.09% | 7.04% | 11.85% |
1 year | 5.15% | 28.60% | 25.12% |
3 years | -47.45% | -20.47% | -7.29% |
5 years | -24.72% | 10.11% | 28.21% |
10 years | 50.26% | 39.04% | 50.11% |
Since Inception | 1'660.27% | 1'997.61% | 1'362.23% |
Annual performance
Share Price | NAV | Benchmark | |
2023 | -18.15% | -7.39% | -4.79% |
2022 | -24.29% | -11.00% | -9.09% |
2021 | 8.34% | -11.45% | 2.98% |
2020 | 19.35% | 24.26% | 15.80% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
Investment Manager | Bellevue Asset Management AG |
Custodian | Bank Julius Bär AG |
Fund Administrator | Bellevue Asset Management AG |
Auditor | Deloitte AG |
Launch date | 09.11.1993 |
Year end closing | 31. Dec |
Management Fee | 1.10% |
ISIN number | CH0038389992 |
Valor number | 3838999 |
Bloomberg | BION SW Equity |
WKN | A0NFN3 |
Legal Information
Legal form | Incorporate company |
SFDR category | Article 8 |
Key data (30.09.2024, base currency CHF)
Beta | 1.35 |
Volatility | 33.02 |
Tracking error | 14.88 |
Active share | 83.73 |
Correlation | 0.92 |
Sharpe ratio | -0.17 |
Information ratio | -0.18 |
Jensen's alpha | -1.71 |
No. of positions | 31 |
Portfolio as at 30.09.2024
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
The Federal Reserve Meeting in September was the focus of much attention when it lowered interest rates by 0.5%, easing monetary policy for the first time in four years. There is an expectation for further rate cuts in 2024 and 2025. Historically lower interest rates tightly correlate with capital inflows in higher-risk sectors such as biotech.
In September we saw positive news from a number of our portfolio companies including Wave Life Sciences, Celldex Therapeutics, Biohaven, Edgewise Therapeutics and Relay Therapeutics. Please find below selected highlights from a few of BB Biotech´s portfolio companies:
Relay Therapeutics (+4.3%, in USD) announced on September 9 positive interim data for RLY-2608. The data showed that despite heavy pre-treatment, patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer who received RLY-2608 600 mg BID in combination with fulvestrant demonstrated clinically meaningful progression-free survival (PFS). Relay raised capital of approximately USD 200 mn following the positive news.
Edgewise Therapeutics (+42.3%, in USD) announced on September 19 positive top-line data of EDG-7500 from the Phase I trial in healthy subjects and the single-dose arm of the Phase II CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomiopathy (HCM).
Celldex Therapeutics (-17.8%, in USD) announced on September 25 positive clinical data for Barzolvolimab, with strong efficacy results in treating chronic spontaneous urticaria, nevertheless its stock price reacted negatively. The primary reasons for this decline were safety concerns related to the treatment, including mild but notable adverse effects such as hair color changes and skin hypopigmentation. These issues, though not dose-dependent, raised questions among investors regarding the drug's broader safety profile.
Wave Life Sciences (+42.9%, in USD) announced on September 24 positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531. The interim analysis was conducted after 24 weeks of 10 mg/kg dosing every two weeks (Q2W), and WVE-N531 demonstrated substantial dystrophin expression and that it was safe and well tolerated. Wave raised capital of approximately USD 230 mn following the positive news.
Dokumente
Show moreShow less